RetiSpec Closes $10M USD to Advance Commercialization of its AI-Driven Eye Test

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

RetiSpec Inc., an innovator in AI-driven eye diagnostics for brain health, recently announced the successful closing of its $10M USD Series A financing. This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease. RetiSpec's clinically validated test aims to help healthcare providers predict amyloid burden, a core biomarker of Alzheimer's disease.

RetiSpec is an OBIO® member, an alumnus of the BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Eurofins CDMO Alphora Inc. Receives Investment from Government of Canada

Next

MOLLI Surgical Acquired by Stryker